Descartes-15

About Cartesian Therapeutics

Cartesian Therapeutics is a clinical-stage biotech leader focused on developing mRNA cell therapies for autoimmune diseases. The company's proprietary platform is designed to engineer a patient's own cells with mRNA to produce therapeutic proteins directly at the site of disease, potentially offering a more targeted and transient treatment approach. Its lead candidate, Descartes-08, is in Phase 2 development for myasthenia gravis, representing a novel application of cell therapy beyond oncology. The company is publicly traded and is advancing a pipeline aimed at bringing 21st-century treatments to patients with autoimmune disorders.

Therapeutic Areas